Approximately 30% percent of subjects with partial seizures are refractory to treatment with
single or combination antiepileptic drugs. The present study will compare the efficacy of two
different dosages of pregabalin CR dosed once daily as compared to placebo, when used as
adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using
a randomized, parallel group design.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.